Secretin Human (DB09532): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Investigational Horizons

1.0 Executive Summary

[Secretin human (DrugBank ID: DB09532) is a synthetic, 27-amino acid peptide hormone that is chemically and biologically identical to endogenous human secretin. Initially recognized over a century ago as the first-ever described hormone, its modern clinical application has been refined into a highly specific diagnostic tool in gastroenterology. Marketed principally under the brand name ChiRhoStim®, this biotech drug serves an indispensable role in the diagnostic evaluation of pancreatic exocrine function, the provocative testing for gastrin-secreting neuroendocrine tumors (gastrinomas), and the procedural facilitation of complex endoscopic retrograde cholangiopancreatography (ERCP). Its mechanism of action is centered on its binding to G-protein coupled secretin receptors, primarily stimulating the secretion of a large volume of bicarbonate-rich fluid from the pancreas and biliary tree, thereby neutralizing duodenal acid and creating an optimal environment for digestion.]

[The pharmacological profile of Secretin human is characterized by a rapid onset of action following intravenous administration and a short elimination half-life of approximately 45 minutes. This pharmacokinetic profile is ideally suited for its function as a diagnostic agent, enabling a transient, controlled physiological challenge with a swift return to baseline. However, this same characteristic presents the primary barrier to its use as a chronic therapeutic agent. The safety profile is favorable, with most adverse events being mild and transient, such as nausea and flushing. The most significant clinical risks are not related to direct toxicity but to the potential for diagnostic misinterpretation due to critical pharmacodynamic interactions with common medications like anticholinergics and acid-suppressing agents.]

[While its established role is firmly rooted in diagnostics, a paradigm shift is underway, driven by a burgeoning body of research that is repositioning secretin as a pleiotropic hormone with profound systemic effects. Investigational studies are revealing its potential to enhance non-invasive pancreatic imaging, its therapeutic utility in functional gastrointestinal disorders like functional dyspepsia, and, most compellingly, its role as a key regulator of energy homeostasis. Emerging evidence implicates secretin in a "gut-brown adipose tissue-brain" axis, where it functions to increase energy expenditure and induce satiety, marking it as a highly promising target for future anti-obesity therapies. Furthermore, nascent research into its hemodynamic effects suggests a potential, previously unrecognized role in cardiovascular and renal physiology. This report provides an exhaustive analysis of Secretin human, synthesizing its molecular characteristics, physiological functions, established clinical applications, and the exciting investigational horizons that are poised to redefine its place in medicine.]

2.0 Molecular Profile and Physicochemical Characteristics

2.1 Structure and Identification

Secretin human is a synthetic, highly purified peptide hormone classified as a biotech drug.[1] It is a member of the secretin-class of hormones and is engineered to be chemically identical in structure and sequence to the naturally occurring secretin peptide found in humans.[1] The transition from historically used, biologically derived porcine secretin (bPS) to a fully synthetic human peptide represents a critical advancement in pharmaceutical quality and clinical safety. The synthetic product, ChiRhoStim®, ensures high purity (≥95-97% by HPLC), batch-to-batch consistency in potency, and eliminates the inherent risks of immunogenicity and zoonotic contaminants associated with animal-derived preparations.[3][ This directly translates to improved reliability and a superior safety profile in diagnostic testing.]

The primary structure of Secretin human consists of a single linear polypeptide chain composed of 27 amino acids.[1][ Its specific amino acid sequence is:]

His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2.3

This sequence is known to support the formation of an α-helical secondary structure, which is crucial for its biological activity and receptor binding.[1] A critical post-translational modification, replicated in the synthetic molecule, is the amidation of the carboxyl-terminal amino acid, valine (Val-27).[1][ This C-terminal amide is a common feature among peptide hormones and serves a vital function in protecting the peptide from rapid degradation by endogenous carboxypeptidases. This structural feature enhances the molecule's stability in circulation, thereby increasing its biological half-life and potency, ensuring it can effectively reach and activate its target receptors before being cleared from the system.]

[Secretin human is identified by a consistent set of chemical and regulatory codes:]

• DrugBank ID: DB09532 [1]
• CAS Number: 108153-74-8 [1]
• UNII: A0426J905J [2]
• Synonyms and Code Names: It is also known as secretin synthetic human, SHS, and by its developmental code name RG1068.[1]

2.2 Physicochemical Properties

[The physical and chemical properties of Secretin human are consistent with those of a moderately sized peptide intended for parenteral administration.]

• Molecular Formula: C130​H220​N44​O40​.[7] A minor discrepancy exists in some sources, which cite the formula as C130​H220​N44​O39​ [3][; this is likely attributable to differences in calculation methods or the specific salt form (e.g., acetate salt) being described, but the core peptide structure remains consistent.]
• Molecular Weight: The calculated molecular weight is approximately 3039.44 to 3039.5 g/mol.[3]
• Physical Form: For clinical use, Secretin human is supplied as a sterile, nonpyrogenic, lyophilized (freeze-dried) white cake powder contained in a vial.[5][ This form ensures long-term stability and allows for reconstitution immediately prior to administration.]
• Solubility: The lyophilized powder is soluble in water to at least 1 mg/mL and is also soluble in 1% acetic acid.[6] For clinical use, it is reconstituted with 0.9% Sodium Chloride Injection, USP.[18]
• Storage and Stability: To maintain its integrity and biological activity, Secretin human requires stringent storage conditions. It must be stored in a freezer at or below -20°C in a desiccated environment and protected from light.[5]

3.0 Mechanism of Action and Physiological Significance

3.1 Endogenous Secretin: A Pleiotropic Regulator

Synthetic Secretin human functions by mimicking the actions of the endogenous hormone, a key regulator of gastrointestinal physiology and a molecule with increasingly recognized systemic effects. Endogenous secretin is synthesized as a 120-amino acid precursor protein, prosecretin, which undergoes proteolytic cleavage to yield the active 27-amino acid peptide hormone.[20]

The primary site of secretin production and secretion is the proximal small intestine. Specialized enteroendocrine cells, known as S-cells, located within the intestinal glands (crypts of Lieberkühn) of the duodenum and proximal jejunum, are responsible for its synthesis and release.[1] The principal physiological trigger for secretin release is the acidification of the duodenal lumen, which occurs when acidic chyme from the stomach enters the small intestine. A duodenal pH below 4.5 is a potent stimulus for S-cells to release secretin into the bloodstream.[1] To a lesser extent, the presence of fatty acids and amino acids in the duodenum also stimulates its release.[1]

Historically viewed as a gastrointestinal hormone, the understanding of secretin has evolved. Its gene is expressed not only in the gut but also in the central nervous system (brain), heart, lungs, and kidneys.[14] This widespread expression, coupled with its actions within the CNS, has led to its reclassification as a neuroendocrine hormone, with roles extending beyond digestion to include osmoregulation, energy homeostasis, and neural function.[1]

3.2 Receptor Binding and Intracellular Signaling

Secretin mediates its diverse biological effects by binding to a specific cell surface receptor, the Secretin Receptor (SCTR). The SCTR is a member of the Class B (or secretin receptor family) of G-protein coupled receptors (GPCRs), a group that also includes receptors for glucagon, vasoactive intestinal peptide (VIP), and gastric inhibitory peptide (GIP).[1]

SCTRs are strategically located on the basolateral membrane of various target cells, allowing them to respond to the hormone circulating in the bloodstream. Key locations include pancreatic ductal cells, biliary epithelial cells (cholangiocytes), gastric parietal cells, and specific neuronal populations within the central nervous system.[1]

[The binding of secretin to its receptor initiates a well-defined intracellular signaling cascade:]

1. G-Protein Activation:[ Ligand-receptor binding induces a conformational change in the SCTR, activating its associated heterotrimeric G-protein, specifically the stimulatory G-protein (Gs​).]
2. Adenylate Cyclase Stimulation:[ The activated alpha subunit of Gs​ (Gsα​) stimulates the enzyme adenylate cyclase.]
3. Second Messenger Production: Adenylate cyclase catalyzes the conversion of adenosine triphosphate (ATP) to the intracellular second messenger, cyclic adenosine monophosphate (cAMP).[1]
4. Downstream Effector Activation: The resulting increase in intracellular cAMP levels activates Protein Kinase A (PKA). PKA then phosphorylates various downstream target proteins, chief among them being the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), an apical membrane chloride channel.[1]

3.3 Systemic Physiological Effects

[The activation of the SCTR-cAMP-PKA pathway translates into a range of coordinated physiological responses throughout the body.]

3.3.1 Pancreatic and Biliary Secretion (Primary Action)

The most prominent and historically recognized action of secretin is the stimulation of pancreatic and biliary secretions. The phosphorylation and activation of the CFTR channel by PKA in pancreatic ductal cells and cholangiocytes leads to the efflux of chloride ions (Cl−) into the ductal lumen. This luminal chloride is then exchanged for intracellular bicarbonate ions (HCO3−​) via a Cl-/HCO3- anion exchanger located on the apical membrane. The net result is the secretion of a large volume of watery, alkaline fluid rich in bicarbonate.[1]

This bicarbonate-rich fluid serves a critical homeostatic function: it neutralizes the acidic chyme arriving from the stomach, raising the duodenal pH to a more neutral range of 6 to 8. This action is essential for two reasons: it protects the duodenal mucosa from acid-induced damage, and it creates the optimal pH environment required for the activity of pancreatic digestive enzymes, such as pancreatic lipase and amylase, which are largely inactive in an acidic milieu.[20][ The diagnostic use of Secretin human is fundamentally a pharmacological challenge to this specific physiological system to assess its functional integrity.]

3.3.2 Gastric Function Modulation

Secretin plays a crucial role in a negative feedback loop that regulates gastric activity. It functions as an "enterogastrone," a hormone released from the intestine that inhibits stomach function. Secretin inhibits the secretion of gastric acid from the parietal cells of the stomach through several proposed mechanisms: direct downregulation of parietal cell activity, inhibition of gastrin release from antral G-cells, and stimulation of the release of somatostatin, another inhibitor of acid secretion.[1] This dual action—stimulating bicarbonate release while simultaneously reducing the acid load from the stomach—demonstrates an elegant, self-regulating system designed to maintain duodenal pH homeostasis. Secretin has also been shown to stimulate the production of pepsin by the stomach.[2]

3.3.3 Osmoregulation and Renal Function

Beyond the gastrointestinal tract, secretin is an important participant in the regulation of body fluid homeostasis. Secretin and its receptors are found in key osmoregulatory centers of the brain, including the magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus, and the posterior pituitary.[20] It is released from the posterior pituitary in response to states of increased plasma osmolality and acts, in part, by stimulating the release of vasopressin (antidiuretic hormone), which promotes water reabsorption in the kidneys.[20] Additionally, secretin has a direct diuretic effect, increasing urinary volume and bicarbonate excretion.[1]

3.3.4 CNS and Metabolic Effects

The presence of secretin and its receptors in brain regions that control appetite and energy balance, such as the arcuate nucleus of the hypothalamus, points to its role as a neuropeptide involved in metabolic regulation.[23] Studies have demonstrated that secretin has an anorectic effect, meaning it promotes satiety and reduces food intake. This action appears to be mediated through both central pathways involving the melanocortin system and peripheral signaling through sensory fibers of the vagus nerve.[20][ The widespread expression of its receptor and its structural similarities to other key metabolic hormones like glucagon provide the biological foundation for the emerging investigational uses of secretin in metabolic disorders, repositioning it from a simple "gut hormone" to a systemic homeostatic regulator.]

4.0 Clinical Pharmacology and Pharmacokinetics

[The clinical pharmacology of Secretin human is defined by its parenteral route of administration and a pharmacokinetic profile characterized by rapid distribution and clearance. This profile is ideally suited for its role as an acute diagnostic agent but presents significant challenges for its potential development as a chronic therapeutic.]

4.1 Administration, Distribution, and Onset

Secretin human is administered exclusively by the intravenous route, typically as a slow bolus injection over a period of one minute.[3] Following administration, its physiological effects are rapid, with stimulation of pancreatic fluid secretion occurring within one minute of injection.[28]

Pharmacokinetic studies in normal human subjects provide insight into its distribution and temporal profile. After an intravenous bolus dose of 0.4 mcg/kg, plasma concentrations of synthetic human secretin peak and then decline rapidly, returning to baseline endogenous levels within 90 to 120 minutes.[1][ This brief duration of action ensures that the physiological challenge is transient and well-controlled.]

The volume of distribution (Vd) has been reported as 2.7 L in one key study conducted for the drug's approval [3], while another source reports a value of 0.16 L/kg.[13][ Both values, while numerically different, suggest that the drug's distribution is largely confined to the vascular and extracellular fluid compartments, with limited penetration into deep tissues, which is typical for a hydrophilic peptide of its size.]

4.2 Metabolism and Elimination

While specific metabolic pathways are not fully detailed in the available documentation, the metabolism of Secretin human is presumed to follow the typical fate of endogenous peptide hormones. As a 27-amino acid peptide, it is expected to be rapidly degraded by peptidases present in the plasma and various tissues throughout the body.[4] Animal studies have indicated that the kidneys play a major role in the clearance of circulating secretin.[29]

[The elimination of Secretin human from the body is rapid, which is a defining feature of its pharmacokinetic profile.]

• Elimination Half-Life (t1/2​): The elimination half-life has been determined to be 45 minutes in a key pharmacokinetic study involving normal volunteers.[1] Another source reports a longer half-life of 2.41 hours [13]; however, the 45-minute value is more frequently cited in the context of the approved drug's clinical profile. It is noteworthy that the half-life of endogenous secretin is even shorter, estimated to be between 2.5 and 4.0 minutes, suggesting the synthetic formulation may possess slightly enhanced stability in circulation.[24]
• Clearance (CL): Total body clearance is high, consistent with its rapid elimination. It has been reported as 580.9 ± 51.3 mL/min in one study [1] and as 6.73 mL/min/kg in another.[13]

This pharmacokinetic profile can be viewed as a "double-edged sword." The rapid clearance and short half-life are ideal attributes for a diagnostic agent. They allow for a precisely timed and brief physiological challenge, minimizing systemic exposure and allowing the patient's body to return to its baseline state quickly. This profile enhances the safety and practicality of the diagnostic tests. Conversely, this same rapid elimination is the single greatest obstacle to the development of Secretin human as a therapeutic agent for chronic conditions, such as obesity or functional dyspepsia. Achieving a sustained therapeutic effect would require continuous intravenous infusion, which is impractical for long-term management. This limitation is the primary driver behind the current research focus on developing long-acting secretin analogues or alternative strategies to prolong the activation of the secretin signaling pathway.[24]

Table 4.1: Summary of Human Secretin Pharmacokinetic Parameters

Parameter	Value(s)	Clinical Significance	Source(s)
Elimination Half-life (t1/2​)	45 minutes	The short duration of action is ideal for an acute diagnostic test, ensuring a rapid return to physiological baseline and minimizing prolonged effects.	1
Volume of Distribution (Vd)	2.7 L or 0.16 L/kg	Suggests distribution is primarily limited to the plasma and extracellular fluid, with minimal tissue sequestration.	3
Clearance (CL)	580.9 ± 51.3 mL/min or 6.73 mL/min/kg	High clearance rate reflects rapid elimination from the body, consistent with the short half-life.	1
Time to Baseline Concentration	90 to 120 minutes	Defines the window of pharmacological activity, confirming that the test is a transient and well-defined physiological challenge.	1

5.0 Approved Diagnostic Applications in Clinical Practice

Synthetic Secretin human is a U.S. Food and Drug Administration (FDA)-approved agent indicated for three specific diagnostic applications in gastroenterology. Its utility lies in its ability to act as a provocative agent, stimulating specific physiological responses that can unmask underlying pathology in the pancreas and stomach.[1][ The reliability of these diagnostic tests is critically dependent on strict adherence to established protocols, as procedural and pre-analytical variables can significantly impact the accuracy of the results.]

5.1 Diagnosis of Exocrine Pancreatic Insufficiency

The primary and most common use of Secretin human is to directly assess the functional reserve of the pancreatic ductal cells. This test, often referred to as the secretin stimulation test, measures the pancreas's ability to secrete bicarbonate in response to a standardized hormonal stimulus. A diminished or absent response is a key indicator of exocrine pancreatic insufficiency, a condition characteristic of diseases such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer.[15]

• Protocol:
• Patient Preparation: The patient must be fasting for a minimum of 12 to 15 hours prior to the procedure to ensure a quiescent baseline state of the gastrointestinal system.[18]
• Dosage: A standard dose of 0.2 mcg/kg of body weight is administered via slow intravenous injection over 1 minute.[18]
• Sample Collection:[ Duodenal fluid, which contains the pancreatic secretions, is collected over a period of 60 minutes following secretin administration. This can be achieved through one of two methods:]

1. Gastroduodenal (Dreiling) Tube Method: This classic method involves the placement of a double-lumen tube under fluoroscopic guidance. One lumen is positioned in the stomach for gastric aspiration, while the other is placed in the duodenum beyond the ampulla of Vater. After collecting a baseline duodenal sample, secretin is injected, and duodenal fluid is continuously aspirated and collected in four consecutive 15-minute aliquots. Verifying correct tube placement by checking for a duodenal aspirate pH of 6 or higher is a critical step to avoid contamination with acidic gastric contents.[18]
2. Endoscopic Method (Endoscopic Pancreatic Function Test - ePFT): A more modern approach involves passing a standard endoscope into the duodenum. After aspirating and discarding all gastric fluid, a baseline duodenal sample (3-5 mL) is collected. Secretin is then administered, and timed aspirates are collected from the post-bulbar duodenum at 15, 30, 45, and 60 minutes.[18]

• Sample Handling: Due to the lability of bicarbonate, collected fluid specimens must be placed on ice immediately and analyzed for bicarbonate concentration promptly. If immediate analysis is not possible, samples must be frozen at -80°C to preserve their integrity.[8]
• Interpretation: The primary endpoint is the peak bicarbonate concentration in any of the collected samples. A normal pancreatic response is characterized by a peak bicarbonate concentration in the range of 80 to 130 mEq/L. A peak concentration below 80 mEq/L is considered abnormal and is consistent with impaired pancreatic exocrine function. Other supportive criteria for dysfunction include a total volume response of less than 2.0 mL/kg/hr and a total bicarbonate output of less than 0.2 mEq/kg/hr.[1]

5.2 Diagnosis of Gastrinoma (Zollinger-Ellison Syndrome)

Secretin human is used as a provocative agent in the diagnosis of gastrinoma, a rare neuroendocrine tumor that autonomously secretes large quantities of the hormone gastrin, leading to severe peptic ulcer disease. The test is based on the paradoxical physiological response of gastrinoma cells to secretin. In a healthy individual, secretin inhibits gastrin release from normal gastric G-cells. However, in a patient with a gastrinoma, secretin paradoxically stimulates the tumor cells to release a surge of gastrin.[1]

• Protocol:
• Patient Preparation: The patient must fast for at least 12 hours. It is of paramount importance that medications that alter gastric acid secretion and gastrin levels, such as H2-receptor antagonists and proton pump inhibitors (PPIs), are discontinued for an appropriate period before the test to prevent false-positive results.[8]
• Dosage: A dose of 0.4 mcg/kg of body weight is administered via intravenous injection over 1 minute. This dose is double that used for pancreatic function testing, reflecting the need for a stronger stimulus for this indication.[18]
• Sample Collection: Two baseline blood samples are drawn to establish the fasting serum gastrin level. Following the secretin injection, serial blood samples are collected at 1, 2, 5, 10, and 30 minutes for serum gastrin measurement.[8]
• Interpretation: A positive test, strongly suggestive of gastrinoma, is defined as an increase in serum gastrin concentration of more than 110 pg/mL above the baseline level in any of the post-injection samples.[8]

5.3 Facilitation of Endoscopic Retrograde Cholangiopancreatography (ERCP)

[Secretin human serves as a valuable procedural adjunct during ERCP, a technically demanding endoscopic procedure used to diagnose and treat conditions of the bile and pancreatic ducts. In certain situations, such as in patients with pancreas divisum (a common congenital anomaly) or post-inflammatory scarring, the endoscopist may have difficulty identifying the ampulla of Vater (the major pancreatic duct opening) or the accessory papilla (the minor opening).]

• Protocol:
• Dosage: During the ERCP procedure, a dose of 0.2 mcg/kg of body weight is administered via intravenous injection over 1 minute.[25]
• Mechanism and Outcome: The administration of secretin rapidly stimulates the pancreas to secrete fluid. This results in a visible flow of clear pancreatic juice from the ductal orifices, effectively highlighting their location for the endoscopist. This "jet sign" can significantly aid in the identification and subsequent cannulation of the desired duct, potentially shortening procedure time and increasing the success rate of difficult cannulations.[1]

[The meticulous nature of these protocols underscores a crucial point: the clinical utility of Secretin human is inextricably linked to the procedural rigor with which the tests are performed. Variables such as patient fasting status, washout of interacting medications, precise sample collection timing, and correct sample handling are not merely procedural details; they are fundamental determinants of diagnostic accuracy. Failure to control these factors can directly lead to erroneous results and subsequent misdiagnosis of serious medical conditions.]

6.0 Safety, Tolerability, and Risk Management

The safety profile of synthetic Secretin human is well-established, and the drug is generally considered safe and well-tolerated when administered as a single intravenous dose in a controlled clinical setting.[17][ The primary risks associated with its use are not related to direct drug toxicity but rather to pharmacodynamic interactions that can compromise the validity of the diagnostic tests.]

6.1 Adverse Event Profile

[Adverse reactions to Secretin human are typically mild, transient, and self-limiting.]

• Common Adverse Events:[ The most frequently reported adverse events in clinical trials involve gastrointestinal and vasomotor symptoms. These include:]
• Nausea [8]
• Vomiting [8]
• Abdominal pain or upset stomach [8]
• Flushing, described as a feeling of warmth or redness of the face, neck, and upper chest [8]
• Less Common Adverse Events: A range of other less frequent side effects have been reported, including anxiety, increased heart rate, clammy skin, diarrhea, faintness, drowsiness, and a tingling sensation in the legs.[16]
• Serious Adverse Events: Severe, acute hypersensitivity reactions, including hives, difficulty breathing, and angioedema, are a theoretical risk with any parenteral peptide administration.[16] However, an allergic reaction to the modern synthetic human secretin formulation has reportedly never been documented.[35] As a precaution, particularly for patients with a history of atopy or when using older porcine-derived formulations, the administration of a small intravenous test dose (e.g., 0.2 mcg) one minute prior to the full diagnostic dose is often recommended to screen for potential allergic reactions.[25]

6.2 Contraindications and Precautions

[While there are few absolute contraindications, several conditions warrant caution as they can interfere with the test's execution or interpretation.]

• Contraindications: The use of Secretin human is contraindicated in patients currently experiencing an episode of acute pancreatitis. The test should be deferred until the acute inflammation has fully resolved.[27]
• Precautions:
• Vagotomy or Inflammatory Bowel Disease (IBD): Patients who have undergone a vagotomy (surgical cutting of the vagus nerve) or who have active IBD may exhibit a blunted or "hyporesponsive" result to the secretin stimulation test. This is believed to be due to the disruption of the vagal-vagal neural pathways that contribute to the full pancreatic secretory response, and it can lead to a false diagnosis of pancreatic exocrine insufficiency.[1]
• Alcoholic or Other Liver Disease: Paradoxically, patients with certain forms of liver disease may demonstrate a greater-than-normal pancreatic fluid volume response to secretin stimulation. This hyperresponse can mask a coexisting pancreatic disease, leading to a false-negative result.[15]
• Pediatric Use: The safety and effectiveness of Secretin human have not been formally established in pediatric populations.[16]
• Pregnancy and Lactation: There is a lack of adequate and well-controlled studies in pregnant or breastfeeding women. Therefore, the use of Secretin human in these populations should only be considered if the potential diagnostic benefit justifies the potential risk to the fetus or infant.[16]

6.3 Clinically Significant Drug Interactions

[The most critical safety considerations for Secretin human involve its pharmacodynamic interactions with other medications. These interactions do not typically cause synergistic toxicity but can profoundly alter the physiological response being measured, leading to invalid test results and potential misdiagnosis.]

• Anticholinergic Drugs: Medications with anticholinergic properties (e.g., atropine, dicyclomine, glycopyrrolate, certain antihistamines and antidepressants) act as functional antagonists to secretin's effects on the pancreas. They can suppress pancreatic secretion, leading to a hyporesponsive test result and a false diagnosis of exocrine insufficiency. It is essential to discontinue these drugs for a period of at least 5 half-lives before administering the secretin stimulation test.[1]
• H2-Receptor Antagonists and Proton Pump Inhibitors (PPIs): These potent acid-suppressing drugs cause a secondary hypergastrinemia (elevated blood gastrin levels). When a secretin stimulation test for gastrinoma is performed in a patient taking these medications, the baseline gastrin level is already high, and the response to secretin can be exaggerated. This "hyperresponse" can mimic the paradoxical rise seen in gastrinoma, leading to a false-positive diagnosis. This highlights that the most significant risk of improper use is not a direct adverse event, but the harm of a misdiagnosis, which could subject a patient to unnecessary and invasive follow-up procedures. Therefore, strict washout periods are mandatory: H2-receptor antagonists (e.g., famotidine) must be stopped for at least 2 days, and PPIs (e.g., esomeprazole) must be stopped for a longer, drug-specific period (e.g., 14 to 30 days) to allow serum gastrin levels to return to a true baseline.[8]

Table 6.1: Drug Interactions with Secretin Human and Clinical Management

Interacting Drug Class	Mechanism of Interaction	Effect on Diagnostic Test	Clinical Recommendation	Source(s)
Anticholinergic Drugs	Pharmacodynamic antagonism of secretin-stimulated pancreatic secretion.	Causes a hyporesponse to pancreatic stimulation testing, potentially leading to a false diagnosis of pancreatic dysfunction.	Discontinue drug at least 5 half-lives prior to the test.	8
H2-Receptor Antagonists	Induces hypergastrinemia, leading to an exaggerated gastrin response to secretin.	Causes a hyperresponse to gastrin stimulation testing, potentially leading to a false diagnosis of gastrinoma.	Discontinue drug at least 2 days prior to the test.	8
Proton Pump Inhibitors (PPIs)	Induces profound and prolonged hypergastrinemia.	Causes a hyperresponse to gastrin stimulation testing, potentially leading to a false diagnosis of gastrinoma.	Discontinue drug for a PPI-specific period (e.g., 14-30 days) to allow gastrin levels to normalize. Consult specific PPI prescribing information.	8

7.0 Commercial Formulations and Regulatory History

7.1 Marketed Product: ChiRhoStim®

The predominant commercial formulation of synthetic human secretin available in the United States is marketed under the brand name ChiRhoStim®. It is manufactured and distributed by ChiRhoClin, Inc., a pharmaceutical company specializing in orphan drugs for theranostic applications.[1] While other brand names such as SecreFlo and Secretin-Ferring have existed historically or in other markets, ChiRhoStim® is the primary product in current U.S. clinical practice.[34]

[ChiRhoStim® is supplied as a sterile, lyophilized powder for reconstitution in vials of two different strengths, providing flexibility for dose calculation based on patient weight and the specific diagnostic indication:]

• 16 mcg vial: This vial is designed to be reconstituted with 8 mL of 0.9% Sodium Chloride Injection, USP. After vigorous shaking to ensure complete dissolution, this yields a final solution with a concentration of 2 mcg/mL.[3]
• 40 mcg vial: This vial is reconstituted with 10 mL of 0.9% Sodium Chloride Injection, USP, to yield a final solution with a concentration of 4 mcg/mL.[8]

The reconstituted solution has a pH range of 3.0 to 6.5.[3] It is imperative that the solution be inspected visually for particulate matter or discoloration before administration. Due to the lack of preservatives, the reconstituted product must be used immediately, and any unused portion must be discarded to ensure sterility and stability.[18]

7.2 Regulatory Pathway and Approval

[The regulatory history of synthetic human secretin in the United States highlights a strategic approach focused on addressing unmet needs in rare diseases.]

• Orphan Drug Designation: On June 16, 1999, the FDA granted Orphan Drug designation to synthetic human secretin (as ChiRhoStim) for the indication "for use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome".[37][ This designation is granted to drugs intended to treat, prevent, or diagnose rare diseases or conditions affecting fewer than 200,000 people in the U.S. It provides the sponsor with incentives such as market exclusivity and tax credits, facilitating the development of drugs for niche populations. This strategic first step allowed the manufacturer to navigate a more focused regulatory path for a clear and specific unmet diagnostic need.]
• New Drug Application (NDA): ChiRhoClin, Inc. submitted a New Drug Application (NDA 21-256) to the FDA on June 14, 2001.[40]
• Initial FDA Approval: Following review of the clinical data, the FDA granted its initial approval for ChiRhoStim® on April 9, 2004.[37]
• Approved Indications:[ The approval was comprehensive and covered the three indications for which the drug is used today:]

1. [Stimulation of pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction.]
2. [Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma.]
3. Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during ERCP.[25]

[This regulatory trajectory, beginning with an orphan designation for a rare condition and culminating in approval for broader (though still specialized) diagnostic applications, demonstrates a successful strategy. The manufacturer leveraged the data and experience gained from the orphan pathway to expand the drug's utility, establishing it as a key diagnostic agent in modern gastroenterology.]

8.0 Investigational Uses and Future Directions

[The collective body of recent and ongoing research is fundamentally redefining Secretin human, transitioning it from a narrowly focused gastrointestinal diagnostic agent to a multi-systemic homeostatic regulator with profound therapeutic potential. Investigations are exploring its utility in advanced medical imaging, functional GI disorders, and several of modern medicine's most challenging chronic diseases, including obesity and heart failure.]

8.1 Advanced Pancreatic Imaging with Secretin-Enhanced MRCP (S-MRCP)

A significant evolution in the diagnostic use of secretin is its application as an adjunct to Magnetic Resonance Cholangiopancreatography (MRCP). Standard MRCP provides high-resolution, static anatomical images of the pancreatic and biliary ducts. The administration of secretin during the scan transforms this into a dynamic, functional study. Secretin stimulates a brisk flow of pancreatic fluid, which distends the main pancreatic duct and its side branches. This distention can improve the visualization of ductal anatomy, unmasking subtle strictures, filling defects, or ductal disruptions that may be inconspicuous on static images.[43]

A large, prospective, multicenter clinical trial (NCT00660335) provided robust evidence for this application. The study enrolled 258 patients with pancreatitis and compared standard MRCP to S-MRCP (using RG1068, the code name for Secretin human), with ERCP serving as the gold standard. The results were compelling: S-MRCP demonstrated a statistically significant improvement in the sensitivity of detecting pancreatic duct abnormalities compared to standard MRCP alone (p<0.0001), with only a minimal loss of specificity. Critically, S-MRCP was shown to be substantially safer than diagnostic ERCP, which carries a significant risk of complications like post-ERCP pancreatitis. The rate of serious adverse events was far lower for the S-MRCP procedure (1.2%) compared to ERCP (20.5%).[43][ This positions S-MRCP as a powerful, non-invasive tool that can provide both anatomical and functional information, potentially reducing the need for higher-risk invasive diagnostic procedures.]

8.2 Therapeutic Potential in Functional Dyspepsia (FD)

Functional dyspepsia is a common and debilitating disorder of gut-brain interaction with limited effective treatments. Based on animal studies suggesting a role for secretin in regulating gastric accommodation (the relaxation of the stomach to accept a meal), researchers hypothesized that a relative secretin deficiency could contribute to FD pathophysiology.[44]

A proof-of-concept, double-blind, crossover clinical trial (NCT03617861) was conducted in both healthy volunteers and patients with FD to test this hypothesis. The study yielded an unexpected but clinically significant finding. While intravenous secretin did not significantly affect gastric accommodation or satiation as hypothesized, it produced a consistent and significant delay in the gastric emptying of a liquid nutrient meal in both healthy and FD cohorts.[44] This observation opens a new therapeutic avenue. Approximately 20% of patients with FD are characterized by abnormally rapid gastric emptying, which can contribute to their symptoms. The findings suggest that activation of the secretin receptor could be a novel therapeutic mechanism specifically for this subset of patients. While the short half-life of secretin itself precludes its use as a chronic oral therapy, this research provides the rationale for developing long-acting secretin receptor agonists or exploring drugs that inhibit secretin's natural degradation, such as neprilysin inhibitors (e.g., sacubitril).[44]

8.3 Metabolic Regulation, Satiety, and Obesity

Perhaps the most transformative area of secretin research is its emerging role in energy homeostasis. A compelling body of evidence from preclinical and clinical studies now implicates secretin as a key hormonal mediator in a "gut-brown adipose tissue-brain" signaling axis that regulates both energy expenditure and energy intake.[24]

• Mechanism and Preclinical Evidence: Secretin has been identified as a potent lipolytic agent and a powerful, non-sympathetic activator of thermogenesis in brown adipose tissue (BAT). The binding of secretin to its receptors on brown adipocytes stimulates heat production. This thermal signal is believed to be relayed to appetite-regulating centers in the brain, such as the hypothalamus, where it functions as a satiation signal to terminate feeding.[22]
• Clinical Evidence: This mechanism has been validated in human studies. A randomized, placebo-controlled clinical trial (NCT04613700) in healthy men demonstrated that a continuous intravenous infusion of secretin significantly decreased subsequent ad libitum food intake by an average of 173 kcal compared to placebo.[46] Other studies have shown that secretin administration increases whole-body energy expenditure and metabolic activity in BAT, as measured by PET imaging.[29]

This dual action—simultaneously reducing energy intake by promoting satiety and increasing energy expenditure through BAT activation—makes the secretin pathway a highly attractive target for the development of novel anti-obesity therapeutics. This represents a potential paradigm shift for secretin, from its current diagnostic niche to a major therapeutic role. The principal challenge, as with other therapeutic applications, remains its very short pharmacokinetic half-life, necessitating the development of long-acting formulations or analogues.[24]

8.4 Cardiovascular and Renal Applications

[The most nascent but potentially impactful area of secretin investigation lies in cardiovascular and renal medicine. Leveraging the known expression of secretin receptors in the heart and kidneys, researchers are beginning to explore its hemodynamic effects.]

Early clinical studies, along with more recent trials, have shown that pharmacological doses of secretin can exert significant cardiovascular effects. In patients with heart failure, secretin infusion was found to increase cardiac output by approximately 20% and to increase stroke volume, suggesting a combination of positive inotropic (contractility-enhancing) and peripheral vasodilator effects.[29] A recent study (NCT03290846) provided further mechanistic support, demonstrating that secretin increases myocardial glucose uptake—an indicator of increased heart work—and also enhances renal filtration.[29][ These findings point to a previously unappreciated role for secretin in fundamental cardiovascular and renal physiology and suggest a completely novel and unexplored potential for secretin-based therapies in the management of heart and kidney failure.]

9.0 Conclusion and Synthesis

[Secretin human (ChiRhoStim®) stands as a testament to the evolution of a century-old physiological discovery into a modern, high-precision diagnostic tool. As a synthetic peptide identical to the endogenous hormone, it offers a safe, reliable, and standardized method for probing the complex physiology of the upper gastrointestinal tract. Its established clinical utility in the diagnosis of exocrine pancreatic insufficiency, the provocative identification of gastrinomas, and the procedural facilitation of ERCP is undisputed and relies on its primary, potent action of stimulating bicarbonate-rich fluid secretion from the pancreas. The drug's pharmacokinetic profile, characterized by rapid onset and short duration of action, is perfectly tailored for these acute diagnostic challenges. However, the successful application of these tests is critically dependent on meticulous clinical protocols, as pharmacodynamic interactions with common medications represent the most significant risk, not of toxicity, but of diagnostic error.]

[Beyond its established role, Secretin human is at the forefront of a clinical and scientific renaissance. A deeper understanding of its widespread receptor expression and pleiotropic functions has catalyzed a wave of investigational research that is expanding its relevance far beyond the confines of diagnostic gastroenterology. Its use in secretin-enhanced MRCP is refining non-invasive imaging, offering a safer alternative to diagnostic ERCP. More profoundly, emerging research is repositioning secretin as a key systemic regulator with significant therapeutic potential. Its demonstrated effects on gastric motility have opened a potential new treatment avenue for functional dyspepsia, while its role in a novel gut-BAT-brain axis—where it simultaneously induces satiety and increases energy expenditure—marks it as one of the most promising new targets in the fight against obesity. Nascent explorations into its cardiovascular and renal effects hint at even broader future applications.]

[The journey of secretin from a simple diagnostic aid to a potential therapy for some of modern medicine's most prevalent chronic diseases is a compelling narrative. The primary obstacle to realizing this therapeutic potential is its fleeting presence in the circulation. Consequently, the future of secretin in medicine will undoubtedly be driven by pharmaceutical innovation aimed at overcoming this pharmacokinetic barrier through the development of long-acting receptor agonists, stabilized peptide analogues, or modulators of its metabolic pathways. Secretin human, the first hormone ever discovered, continues to reveal new layers of biological significance, promising to remain a molecule of intense scientific and clinical interest for the foreseeable future.]

Works cited

1. Secretin human: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 9, 2025, https://go.drugbank.com/drugs/DB09532
2. Secretin Human - PubChem, accessed September 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Secretin-human
3. C:\Documents and Settings\My Documents\NDA 21-256\NDA 21 ..., accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21256_humansecretin_lbl.pdf
4. Definition of synthetic human secretin - NCI Drug Dictionary, accessed September 9, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/secretin-human
5. Secretin human =97 HPLC,powder 108153-74-8 - Sigma-Aldrich, accessed September 9, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/s7147
6. Secretin (human) | Secretin Receptor Agonists - R&D Systems, accessed September 9, 2025, https://www.rndsystems.com/products/secretin-human_1918
7. Secretin, human; CAS 108153-74-8 - Aapptec Peptides, accessed September 9, 2025, https://www.peptide.com/product/secretin-human-108153-74-8/
8. human secretin injection, powder, lyophilized, for solution CHIRHOSTIM 40 - DailyMed, accessed September 9, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd
9. Secretin (human) - Tocris Bioscience, accessed September 9, 2025, https://www.tocris.com/products/secretin-human_1918
10. Secretin, human - GenScript, accessed September 9, 2025, https://www.genscript.com/peptide/RP10249-Secretin_human.html
11. Drug Information - HORDB, accessed September 9, 2025, http://hordb.cpu-bioinfor.org/druginfor.php?id=hd00054
12. 108153-74-8・Secretin (Human)・334-41651[Detail Information, accessed September 9, 2025, https://labchem-wako.fujifilm.com/us/product/detail/W01H014165-V.html
13. secretin human - Drug Central, accessed September 9, 2025, https://drugcentral.org/drugcard/2548
14. Secretin, human - CPC Scientific, accessed September 9, 2025, https://cpcscientific.com/products/catalog-peptides/SECT-001/
15. 21-256 Synthetic Human Secretin Final Print Label - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-256_Synthetic%20Human%20Secretin_Prntlbl.pdf
16. ChiRhoStim (Human Secretin): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 9, 2025, https://www.rxlist.com/chirhostim-drug.htm
17. Safety Data Sheet ChiRhoStim®, Human Secretin for Injection, Acetate - ChiRhoClin, accessed September 9, 2025, https://www.chirhoclin.com/wp-content/uploads/2025/07/CRC-100_ChiRhoStim-Human-Secretin-for-Injection-Acetate-1.pdf
18. ChiRhoStim Dosage Guide - Drugs.com, accessed September 9, 2025, https://www.drugs.com/dosage/chirhostim.html
19. ChiRhoStim (secretin) dosing, indications, interactions, adverse effects, and more, accessed September 9, 2025, https://reference.medscape.com/drug/chirhostim-secretin-342080
20. Physiology, Secretin - StatPearls - NCBI Bookshelf, accessed September 9, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537116/
21. The physiological roles of secretin and its receptor - Annals of Translational Medicine, accessed September 9, 2025, https://atm.amegroups.org/article/view/1732/html
22. SCT - Secretin - Homo sapiens (Human) | UniProtKB | UniProt, accessed September 9, 2025, https://www.uniprot.org/uniprotkb/P09683/entry
23. Secretin - Wikipedia, accessed September 9, 2025, https://en.wikipedia.org/wiki/Secretin
24. Effects of a long-acting secretin peptide analog alone and in combination with a GLP-1R agonist in a diet-induced obesity mouse model - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10344952/
25. PORCINE SECRETIN for injection Label - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021136s012s013_021209s002lbl.pdf
26. Secretin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 9, 2025, https://www.drugs.com/dosage/secretin.html
27. ChiRhoStim - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021256s002lbl.pdf
28. ChiRhoClin - ChiRhoClin, accessed September 9, 2025, https://www.chirhoclin.com/
29. Pleiotropic Effects of Secretin: A Potential Drug Candidate ... - Frontiers, accessed September 9, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.737686/full
30. Human Secretin: Side Effects, Dosage & Uses - Drugs.com, accessed September 9, 2025, https://www.drugs.com/human_secretin.html
31. Secretin stimulation test: MedlinePlus Medical Encyclopedia Image, accessed September 9, 2025, https://medlineplus.gov/ency/imagepages/8909.htm
32. Secretin (intravenous route) - Side effects & uses - Mayo Clinic, accessed September 9, 2025, https://www.mayoclinic.org/drugs-supplements/secretin-intravenous-route/description/drg-20406470
33. ChiRhoStim - Drug Summary - PDR.Net, accessed September 9, 2025, https://www.pdr.net/drug-summary/ChiRhoStim-human-secretin-2804
34. SecreFlo (Secretin): Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed September 9, 2025, https://www.rxlist.com/secreflo-drug.htm
35. ChiRhoStim Synthetic Human Secretin - ChiRhoClin, accessed September 9, 2025, https://www.chirhoclin.com/products/chirhostim-synthetic-human-secretin/
36. Secretin | C130H219N43O42 | CID 16129665 - PubChem, accessed September 9, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Secretin
37. Search Orphan Drug Designations and Approvals - FDA, accessed September 9, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=120798
38. Secretin - brand name list from Drugs.com, accessed September 9, 2025, https://www.drugs.com/ingredient/secretin.html
39. Secretin (Professional Patient Advice) - Drugs.com, accessed September 9, 2025, https://www.drugs.com/ppa/secretin.html
40. 21-256 Synthetic Human Secretin Approval - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-256_Synthetic%20Human%20Secretin_Approv.pdf
41. ChiRhoStim (secretin synthetic human) FDA Approval History - Drugs.com, accessed September 9, 2025, https://www.drugs.com/history/chirhostim.html
42. Drug Approval Package: Human Secretin Injection NDA #021256 - accessdata.fda.gov, accessed September 9, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-256_SyntheticHS.cfm
43. Administration of secretin (RG1068) increases the sensitivity of ..., accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/24906040/
44. Secretin effects on gastric functions, hormones and symptoms in ..., accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7191464/
45. Effect of Secretin in Functional Dyspepsia and Healthy Subjects | ClinicalTrials.gov, accessed September 9, 2025, https://clinicaltrials.gov/study/NCT03617861
46. Secretin infusion decreases food intake in healthy men-a randomized, placebo-controlled, double-blind, crossover study - PubMed, accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/39556772/
47. Novel effects of the gastrointestinal hormone secretin on cardiac ..., accessed September 9, 2025, https://journals.physiology.org/doi/10.1152/ajpendo.00260.2021